Stockreport

Melt doses first subject in Phase III trial of non-opioid sedation tablet [Yahoo! Finance]

Catalent, Inc.  (CTLT) 
Last catalent, inc. earnings: 2/3 07:30 am Check Earnings Report
US:NYSE Investor Relations: investor.catalent.com
PDF A sublingual tablet, MELT-300 combines midazolam and ketamine, aiming to provide a new sedation alternative. The randomised, double-blind, three-arm study is designed [Read more]